Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin

R. D. Snyder, G. N. Hortobagyi, G. P. Bodey, J. U. Gutterman, E. M. Hersh

Research output: Contribution to journalArticle

Abstract

A study was undertaken to investigate the addition of heparin and pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front‐line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of pseudomonas vaccine that seemed to be tolerated has been established.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalJournal of Surgical Oncology
Volume16
Issue number1
DOIs
StatePublished - 1981

Keywords

  • BCNU
  • anticoagulation in melanoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin'. Together they form a unique fingerprint.

  • Cite this